Nasal, oral antiseptics show antiviral activity against SARS-CoV-2

By The Science Advisory Board staff writers

May 15, 2020 -- Veloce BioPharma has reported that its nasal and oral antiseptics are effective against SARS-CoV-2, the virus responsible for COVID-19.

Researchers at the Institute for Antiviral Research at Utah State University tested the company's Halodine nasal and oral antiseptic preparations against the novel coronavirus. They found the solutions were effective against SARS-CoV-2 even when diluted far below available commercial strength, according to Veloce BioPharma.

The Halodine solutions contain a proprietary povidone-iodine antiseptic formulation for repeated nasal and oral use. It is the first iodine-based antiseptic to be active against the novel coronavirus, the lead author noted in a press release.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.